<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363319">
  <stage>Registered</stage>
  <submitdate>29/11/2012</submitdate>
  <approvaldate>25/03/2013</approvaldate>
  <actrnumber>ACTRN12613000325707</actrnumber>
  <trial_identification>
    <studytitle>Waitemata Community Wellness Biobank: analysis of stored biological samples to evaluate health outcomes and plan public health strategies
</studytitle>
    <scientifictitle>Waitemata Community Wellness Biobank: analysis of stored biological samples to evaluate health outcomes and plan public health strategies
</scientifictitle>
    <utrn>U1111-1137-4472 </utrn>
    <trialacronym>NSH Biobank</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular disease</healthcondition>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Obesity and metabolic disease</healthcondition>
    <healthcondition>Gastrointestinal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an observation of the exposure of an individual to current medical standard of care e.g. current medicines etc and environmental exposure e.g. diet and smoking. This exposure will be compared with long-term health outcomes using electronic medical records and coded DRGs. Genomic DNA from whole blood and plasma will be stored on patients. Genomic, proteomic and metabolomic analysis will be applied to the samples to assess interactions between the individual, drugs and environment. Data will also be aggregated from electronic clinical records and patient questionnaires. The patient questionnaire will be completed at the beginning of the study and will not be repeated. Blood samples will be collected at 6mths, 1, 2, 3, 5 and 10 year periods.</interventions>
    <comparator>The historical control will be the baseline results for the same patient if the patient represents to hospital or clinic and has further blood drawn. Alternatively the historical control will be patients treated in the past with older treatment practices.</comparator>
    <control>Historical</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of cardiovascular disease as assessed using data linkage to electronic medical records</outcome>
      <timepoint>6 months, 12 months, 2 years, 3 years, 5 years, 10 years. Participants will not necessarily be recalled. Outcomes will be assessed using electronic medical records.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of diabetes complications and control using the HBA1C assay

</outcome>
      <timepoint>6mths, 12mths, 2yrs, 3yrs, 5yrs, 10yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of gastrointestinal cancer assessed through colonoscopy results in electronic medical records, and ICD10 diagnosis codes.</outcome>
      <timepoint>6mths, 12mths, 2yrs, 3yrs, 5yrs, 10yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of inflammatory bowel disease using inflammatory markers, patient diary and/or electronic medical records.</outcome>
      <timepoint>6mths, 12mths, 2yrs. 3yrs, 5yrs, 10yrs</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients presenting to hospital via ambulatory clinics or the emergency department. Community patients from primary care will also be included.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>110</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Nil</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Case control</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2013</anticipatedstartdate>
    <actualstartdate>5/05/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>5000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>North Shore hospital</primarysponsorname>
    <primarysponsoraddress>124 Shakespeare Rd, Westlake 0622, New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Theranostics Lab</fundingname>
      <fundingaddress>26 Volcanic St,
Mt Eden,
Auckland 1041</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>New Zealand Institute of Clinical Excellence</sponsorname>
      <sponsoraddress>North Shore hospital clinical laboratory,
Shakespeare Rd,
Takapuna,
Auckland 0622</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This resource/biobank has two main aims. The first aim is to gain a better understanding of the interactions between genes, environment and the way we live that influence health or cause diseases.  The second aim is to use this understanding to develop new drugs, genetic tests and treatments and to plan public health strategies. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern A Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>1/04/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>4/12/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Patrick Gladding</name>
      <address>26 Volcanic St,
Mt Eden
Auckland 1041</address>
      <phone>+64220424325</phone>
      <fax />
      <email>patrickg@theranosticslab.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Patrick A. Gladding</name>
      <address>26 Volcanic St,
Mt Eden
Auckland 1041</address>
      <phone>+64220424325</phone>
      <fax />
      <email>patrickg@theranosticslab.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Patrick A. Gladding</name>
      <address>26 Volcanic St,
Mt. Eden,
Auckland 1041</address>
      <phone>+64220424325</phone>
      <fax />
      <email>patrickg@theranosticslab.com</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>